These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 1906903)
21. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Pritchett EL; Wilkinson WE Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055 [TBL] [Abstract][Full Text] [Related]
23. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. Cardiac Arrhythmia Suppression Trial (CAST) Investigators N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403 [TBL] [Abstract][Full Text] [Related]
24. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. Bigger JT Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253 [TBL] [Abstract][Full Text] [Related]
25. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Feld GK; Chen PS; Nicod P; Fleck RP; Meyer D Am J Cardiol; 1990 Aug; 66(3):378-83. PubMed ID: 2114784 [No Abstract] [Full Text] [Related]
27. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891 [TBL] [Abstract][Full Text] [Related]
28. Consequences of the Cardiac Arrhythmia Suppression Trial: calamity or clarity? Maloney JD Cleve Clin J Med; 1989 Sep; 56(6):649-53. PubMed ID: 2509109 [No Abstract] [Full Text] [Related]
29. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Myerburg RJ; Kessler KM; Cox MM; Huikuri H; Terracall E; Interian A; Fernandez P; Castellanos A Circulation; 1989 Dec; 80(6):1571-9. PubMed ID: 2480856 [TBL] [Abstract][Full Text] [Related]
30. Ventricular arrhythmias: risk stratification and approach to therapy after the Cardiac Arrhythmia Suppression Trial (CAST). Prystowsky EN; Katz A; Knilans TK Pacing Clin Electrophysiol; 1990 Nov; 13(11 Pt 2):1480-7. PubMed ID: 1702527 [No Abstract] [Full Text] [Related]
31. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082 [TBL] [Abstract][Full Text] [Related]
32. From the Food and Drug Administration. Nightingale SL JAMA; 1989 Jun; 261(23):3368. PubMed ID: 2498536 [No Abstract] [Full Text] [Related]
33. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101 [TBL] [Abstract][Full Text] [Related]
34. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Kuck KH; Kunze KP; Schlüter M; Duckeck W Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166 [TBL] [Abstract][Full Text] [Related]
35. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents. Chase SL; Sloskey GE Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276 [TBL] [Abstract][Full Text] [Related]